Cytokinetics (CYTK) Share-based Compensation (2010 - 2026)

Cytokinetics (CYTK) has reported Share-based Compensation for 17 consecutive years, with $13.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 274.18% year-over-year to $13.1 million; the TTM figure through Mar 2026 stood at $13.1 million (down 83.57% YoY), while the FY2025 annual figure was $112.3 million, up 14.76% from the prior year.
• Share-based Compensation retreated to $13.1 million in Q1 2026 per CYTK's latest filing, from $111.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $111.0 million in Q4 2025 and bottomed at -$42.1 million in Q4 2023.
• Historically, Share-based Compensation has averaged $17.4 million across 5 years, with a median of $15.2 million in 2023.
• On a YoY basis, Share-based Compensation climbed as much as 2061.31% in 2023 and fell as far as 676.97% in 2023.
• Cytokinetics' Share-based Compensation stood at $7.3 million in 2022, then sank by 676.97% to -$42.1 million in 2023, then surged by 162.41% to $26.2 million in 2024, then surged by 323.01% to $111.0 million in 2025, then sank by 88.2% to $13.1 million in 2026.
• Business Quant data shows CYTK's Share-based Compensation at $13.1 million in Q1 2026, $111.0 million in Q4 2025, and $1.3 million in Q3 2025.